CoChat
Sign Up
Cited by 107

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Lipoprotein(a) catabolism: a case of multiple receptors

McCormick, Sally P.A., Schneider, Wolfgang J.·2019·Pathology
DOI 10.1016/j.pathol.2018.11.003
Open this paper in CoChat — free account

Abstract

Lipoprotein(a) [Lp(a)] is an apolipoprotein B (apoB)-containing plasma lipoprotein similar in structure to low-density lipoprotein (LDL). Lp(a) is more complex than LDL due to the presence of apolipoprotein(a) [apo(a)], a large glycoprotein sharing extensive homology with plasminogen, which confers some unique properties onto Lp(a) particles. ApoB and apo(a) are essential for the assembly and catabolism of Lp(a); however, other proteins associated with the particle may modify its metabolism. Lp(a) specifically carries a cargo of oxidised phospholipids (OxPL) bound to apo(a) which stimulates many proinflammatory pathways in cells of the arterial wall, a key property underlying its pathogenicity and association with cardiovascular disease (CVD). While the liver and kidney are the major tissues implicated in Lp(a) clearance, the pathways for Lp(a) uptake appear to be complex and are still under investigation. Biochemical studies have revealed an exceptional array of receptors that associate with Lp(a) either via its apoB, apo(a), or OxPL components. These receptors fall into five main categories, namely 'classical' lipoprotein receptors, toll-like and scavenger receptors, lectins, and plasminogen receptors. The roles of these receptors have largely been dissected by genetic manipulation in cells or mice, although their relative physiological importance for removal of Lp(a) from the circulation remains unclear. The LPA gene encoding apo(a) has an overwhelming effect on Lp(a) leve…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pathol.2018.11.003

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 127

  1. Berg, 1963, A new serum type system in man–the Lp system, Acta Pathol Microbiol Scand, 59, 369, 10.1111/j.1699-0463.1963.tb01808.x · DOI
  2. Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604 · DOI · Paper page
  3. Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 · DOI · Paper page
  4. Varvel, 2016, Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States, Arterioscler Thromb Vasc Biol, 36, 2239, 10.1161/ATVBAHA.116.308011 · DOI
  5. Kamstrup, 2008, Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study, Circulation, 117, 176, 10.1161/CIRCULATIONAHA.107.715698 · DOI
  6. Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063 · DOI · Paper page
  7. Smolders, 2007, Lipoprotein (a) and stroke: a meta-analysis of observational studies, Stroke, 38, 1959, 10.1161/STROKEAHA.106.480657 · DOI
  8. Thanassoulis, 2013, Genetic associations with valvular calcification and aortic stenosis, N Engl J Med, 368, 503, 10.1056/NEJMoa1109034 · DOI · Paper page
  9. Nordestgaard, 2016, Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology, J Lipid Res, 57, 1953, 10.1194/jlr.R071233 · DOI · Paper page
  10. Boffa, 2018, The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?, Curr Opin Lipidol, 29, 259, 10.1097/MOL.0000000000000499 · DOI
  11. Gencer, 2017, Lipoprotein(a): the revenant, Eur Heart J, 38, 1553, 10.1093/eurheartj/ehx033 · DOI
  12. Kamstrup, 2014, Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population, J Am Coll Cardiol, 63, 470, 10.1016/j.jacc.2013.09.038 · DOI · Paper page
  13. Willeit, 2018, Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials, Lancet, 392, 1311, 10.1016/S0140-6736(18)31652-0 · DOI · Paper page
  14. Ellis, 2017, The renaissance of lipoprotein(a): brave new world for preventive cardiology?, Prog Lipid Res, 68, 57, 10.1016/j.plipres.2017.09.001 · DOI
  15. Tsimikas, 2012, Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies, J Am Coll Cardiol, 60, 716, 10.1016/j.jacc.2012.04.038 · DOI
  16. Boffa, 2016, Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?, J Lipid Res, 57, 745, 10.1194/jlr.R060582 · DOI · Paper page
  17. Kostner, 2018, Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate, Atherosclerosis, 274, 16, 10.1016/j.atherosclerosis.2018.04.032 · DOI
  18. Torzewski, 2017, Lipoprotein(a) associated molecules are prominent components in plasma and valve leaflets in calcific aortic valve stenosis, JACC Basic Transl Sci, 2, 229, 10.1016/j.jacbts.2017.02.004 · DOI
  19. van der Valk, 2016, Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans, Circulation, 134, 611, 10.1161/CIRCULATIONAHA.116.020838 · DOI
  20. Yu, 2017, Lipoprotein(a) induces human aortic valve interstitial cell calcification, JACC Basic Transl Sci, 2, 358, 10.1016/j.jacbts.2017.03.015 · DOI
  21. Tsimikas, 2018, NHLBI working group recommendations to reduce lipoprotein(a)–mediated risk of cardiovascular disease and aortic stenosis, J Am Coll Cardiol, 71, 177, 10.1016/j.jacc.2017.11.014 · DOI
  22. Yeang, 2015, 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering, Curr Opin Lipidol, 26, 169, 10.1097/MOL.0000000000000171 · DOI
  23. Vuorio, 2017, Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a), Eur Heart J, 38, 3555, 10.1093/eurheartj/ehx546 · DOI
  24. van Capelleveen, 2016, Current therapies for lowering lipoprotein (a), J Lipid Res, 57, 1612, 10.1194/jlr.R053066 · DOI
  25. Merki, 2008, Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice, Circulation, 118, 743, 10.1161/CIRCULATIONAHA.108.786822 · DOI · Paper page
  26. Utermann, 1989, The mysteries of lipoprotein(a), Science, 246, 904, 10.1126/science.2530631 · DOI · Paper page
  27. van der Hoek, 1993, The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms, Hum Mol Genet, 2, 361, 10.1093/hmg/2.4.361 · DOI
  28. Lackner, 1991, Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis, J Clin Invest, 87, 2153, 10.1172/JCI115248 · DOI
  29. Tomlinson, 1989, Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of synthesis, J Biol Chem, 264, 5957, 10.1016/S0021-9258(18)83643-2 · DOI
  30. Gabel, 1998, Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100, Biochemistry, 37, 7892, 10.1021/bi973186w · DOI
  31. Becker, 2004, Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly, J Biol Chem, 279, 2679, 10.1074/jbc.M309414200 · DOI
  32. Becker, 2001, Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a), J Biol Chem, 276, 36155, 10.1074/jbc.M104789200 · DOI
  33. Liu, 2004, Mutation of lysine residues in apolipoprotein B-100 causes defective lipoprotein[a] formation, J Lipid Res, 45, 63, 10.1194/jlr.M300071-JLR200 · DOI
  34. Koschinsky, 1993, Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100, J Biol Chem, 268, 19819, 10.1016/S0021-9258(19)36587-1 · DOI
  35. McCormick, 1995, Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a), Proc Natl Acad Sci USA, 92, 10147, 10.1073/pnas.92.22.10147 · DOI
  36. Callow, 1995, Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo, J Biol Chem, 270, 23914, 10.1074/jbc.270.41.23914 · DOI
  37. Chiesa, 1992, Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a), J Biol Chem, 267, 24369, 10.1016/S0021-9258(18)35775-2 · DOI
  38. White, 1994, Intracellular processing of apo(a) in primary baboon hepatocytes, Chem Phys Lipids, 67–68, 123, 10.1016/0009-3084(94)90131-7 · DOI
  39. White, 1994, Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes, J Biol Chem, 269, 28716, 10.1016/S0021-9258(19)61964-2 · DOI
  40. Lobentanz, 1998, Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells, Biochemistry, 37, 5417, 10.1021/bi972761t · DOI
  41. Demant, 2001, The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans, Atherosclerosis, 157, 325, 10.1016/S0021-9150(00)00732-2 · DOI
  42. Bonen, 1997, Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a), J Biol Chem, 272, 5659, 10.1074/jbc.272.9.5659 · DOI
  43. Edelstein, 1994, Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes, Chem Phys Lipids, 67–68, 135, 10.1016/0009-3084(94)90132-5 · DOI
  44. Frischmann, 2012, In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a), Atherosclerosis, 225, 322, 10.1016/j.atherosclerosis.2012.09.031 · DOI
  45. Su, 1998, Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement, J Clin Endocrinol Metab, 83, 3267
  46. Cohn, 1991, Plasma lipoprotein distribution of apolipoprotein(a) in the fed and fasted states, Atherosclerosis, 90, 59, 10.1016/0021-9150(91)90244-W · DOI
  47. Gaubatz, 2001, Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins, J Lipid Res, 42, 2058, 10.1016/S0022-2275(20)31535-2 · DOI
  48. Diffenderfer, 2016, Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a), Metabolism, 65, 381, 10.1016/j.metabol.2015.10.031 · DOI
  49. Mikl, 2011, Softness of atherogenic lipoproteins: a comparison of very low density lipoprotein (VLDL) and low density lipoprotein (LDL) using elastic incoherent neutron scattering (EINS), J Am Chem Soc, 133, 13213, 10.1021/ja203679g · DOI
  50. Wang, 2000, Well-defined regions of apolipoprotein B-100 undergo conformational change during its intravascular metabolism, Arterioscler Thromb Vasc Biol, 20, 1301, 10.1161/01.ATV.20.5.1301 · DOI
  51. Becker, 2006, Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation, Biochemistry, 45, 9919, 10.1021/bi060283t · DOI
  52. Jenner, 2005, The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings, Metabolism, 54, 361, 10.1016/j.metabol.2004.10.001 · DOI
  53. von Zychlinski, 2011, Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding, J Proteomics, 74, 2881, 10.1016/j.jprot.2011.07.008 · DOI
  54. Blencowe, 1995, Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein, J Biol Chem, 270, 31151, 10.1074/jbc.270.52.31151 · DOI
  55. Bouchareb, 2015, Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve, Circulation, 132, 677, 10.1161/CIRCULATIONAHA.115.016757 · DOI
  56. Bergmark, 2008, A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma, J Lipid Res, 49, 2230, 10.1194/jlr.M800174-JLR200 · DOI
  57. Nsaibia, 2016, Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease, J Intern Med, 280, 509, 10.1111/joim.12519 · DOI
  58. Schneider, 1982, Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight, J Biol Chem, 257, 2664, 10.1016/S0021-9258(18)34975-5 · DOI · Paper page
  59. Cain, 2005, Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a], J Lipid Res, 46, 2681, 10.1194/jlr.M500249-JLR200 · DOI · Paper page
  60. Hrzenjak, 2003, Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism, Biochem J, 376, 765, 10.1042/bj20030932 · DOI · Paper page
  61. Havekes, 1981, Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts, FEBS Lett, 132, 169, 10.1016/0014-5793(81)81153-2 · DOI
  62. Floren, 1981, Uptake of Lp (a) lipoprotein by cultured fibroblasts, Biochem Biophys Res Commun, 102, 636, 10.1016/S0006-291X(81)80179-9 · DOI · Paper page
  63. Krempler, 1983, Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man, J Clin Invest, 71, 1431, 10.1172/JCI110896 · DOI · Paper page
  64. Tam, 1996, Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2, J Lipid Res, 37, 518, 10.1016/S0022-2275(20)37595-7 · DOI · Paper page
  65. Romagnuolo, 2015, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor, J Biol Chem, 290, 11649, 10.1074/jbc.M114.611988 · DOI · Paper page
  66. Romagnuolo, 2017, Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9, PLoS One, 12, e0180869, 10.1371/journal.pone.0180869 · DOI
  67. Hofmann, 1990, Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice, J Clin Invest, 85, 1542, 10.1172/JCI114602 · DOI · Paper page
  68. Lingenhel, 1998, Concentrations of the atherogenic Lp(a) are elevated in FH, Eur J Hum Genet, 6, 50, 10.1038/sj.ejhg.5200152 · DOI · Paper page
  69. Alonso, 2014, Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation, J Am Coll Cardiol, 63, 1982, 10.1016/j.jacc.2014.01.063 · DOI · Paper page
  70. Reblin, 1997, Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein, J Lipid Res, 38, 2103, 10.1016/S0022-2275(20)37140-6 · DOI · Paper page
  71. Rader, 1995, The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans, J Clin Invest, 95, 1403, 10.1172/JCI117794 · DOI · Paper page
  72. Knight, 1991, Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects, Atherosclerosis, 87, 227, 10.1016/0021-9150(91)90025-X · DOI · Paper page
  73. Knight, 1994, Lp(a) catabolism in hypercholesterolaemic individuals, Chem Phys Lipids, 67–68, 233, 10.1016/0009-3084(94)90142-2 · DOI · Paper page
  74. Carmena, 1996, Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect, Arterioscler Thromb Vasc Biol, 16, 129, 10.1161/01.ATV.16.1.129 · DOI · Paper page
  75. 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
  76. Yeang, 2016, Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a), J Clin Lipidol, 10, 594, 10.1016/j.jacl.2016.01.005 · DOI
  77. Desai, 2013, Circulation, 128, 962, 10.1161/CIRCULATIONAHA.113.001969 · DOI
  78. Gaudet, 2014, Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials), Am J Cardiol, 114, 711, 10.1016/j.amjcard.2014.05.060 · DOI
  79. Raal, 2014, Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials, J Am Coll Cardiol, 63, 1278, 10.1016/j.jacc.2014.01.006 · DOI
  80. Villard, 2016, PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab, JACC Basic Transl Sci, 1, 419, 10.1016/j.jacbts.2016.06.006 · DOI · Paper page
  81. Croyal, 2018, PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate, Clin Sci (Lond), 132, 1075, 10.1042/CS20180040 · DOI
  82. Watts, 2018, Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics, Eur Heart J, 39, 2577, 10.1093/eurheartj/ehy122 · DOI
  83. Reyes-Soffer, 2017, Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans, Circulation, 135, 352, 10.1161/CIRCULATIONAHA.116.025253 · DOI · Paper page
  84. Argraves, 1997, The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor, J Clin Invest, 100, 2170, 10.1172/JCI119753 · DOI · Paper page
  85. Strickland, 2002, Diverse roles for the LDL receptor family, Trends Endocrinol Metabol, 13, 66, 10.1016/S1043-2760(01)00526-4 · DOI · Paper page
  86. Leeb, 2014, Clusterin is a ligand for apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and signals via the Reelin-signaling pathway, J Biol Chem, 289, 4161, 10.1074/jbc.M113.529271 · DOI · Paper page
  87. Beisiegel, 1989, The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein, Nature, 341, 162, 10.1038/341162a0 · DOI
  88. Marz, 1993, Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor, FEBS Lett, 325, 271, 10.1016/0014-5793(93)81087-G · DOI · Paper page
  89. von Zychlinski, 2014, Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins, J Proteomics, 106, 181, 10.1016/j.jprot.2014.04.030 · DOI
  90. Albers, 2007, Evidence mounts for a role of the kidney in lipoprotein(a) catabolism, Kidney Int, 71, 961, 10.1038/sj.ki.5002240 · DOI
  91. Niemeier, 1999, Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro, Arterioscler Thromb Vasc Biol, 19, 552, 10.1161/01.ATV.19.3.552 · DOI
  92. Tavori, 2016, PCSK9 association with lipoprotein(a), Circ Res, 119, 29, 10.1161/CIRCRESAHA.116.308811 · DOI
  93. Akira, 2006, Pathogen recognition and innate immunity, Cell, 124, 783, 10.1016/j.cell.2006.02.015 · DOI
  94. Di Gioia, 2015, Toll-like receptor co-receptors as master regulators of the immune response, Mol Immunol, 63, 143, 10.1016/j.molimm.2014.05.008 · DOI
  95. Seimon, 2010, Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress, Cell Metabol, 12, 467, 10.1016/j.cmet.2010.09.010 · DOI · Paper page
  96. Mack, 2017, A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms, J Lipid Res, 58, 1834, 10.1194/jlr.M076232 · DOI · Paper page
  97. Feingold, 2008, Inflammation stimulates the expression of PCSK9, Biochem Biophys Res Commun, 374, 341, 10.1016/j.bbrc.2008.07.023 · DOI
  98. Scipione, 2015, Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a), J Lipid Res, 56, 2273, 10.1194/jlr.M060210 · DOI
  99. Acton, 1996, Identification of scavenger receptor SR-BI as a high density lipoprotein receptor, Science, 271, 518, 10.1126/science.271.5248.518 · DOI · Paper page
  100. Wang, 1998, Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice, J Biol Chem, 273, 32920, 10.1074/jbc.273.49.32920 · DOI
  101. Zanoni, 2018, Endocytosis of lipoproteins, Atherosclerosis, 275, 273, 10.1016/j.atherosclerosis.2018.06.881 · DOI
  102. Yang, 2013, Scavenger receptor-BI is a receptor for lipoprotein(a), J Lipid Res, 54, 2450, 10.1194/jlr.M038877 · DOI · Paper page
  103. Sharma, 2015, Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids, J Lipid Res, 56, 1318, 10.1194/jlr.M056150 · DOI · Paper page
  104. Yang, 2016, SCARB1 gene variants are associated with the phenotype of combined high high-density lipoprotein cholesterol and high lipoprotein (a), Circ Cardiovasc Genet, 9, 408, 10.1161/CIRCGENETICS.116.001402 · DOI
  105. Igdoura, 2017, Asialoglycoprotein receptors as important mediators of plasma lipids and atherosclerosis, Curr Opin Lipidol, 28, 209, 10.1097/MOL.0000000000000395 · DOI · Paper page
  106. Garner, 2001, Structural elucidation of the N- and O-glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance, J Biol Chem, 276, 22200, 10.1074/jbc.M102150200 · DOI
  107. Camby, 2006, Galectin-1: a small protein with major functions, Glycobiology, 16, 10.1093/glycob/cwl025 · DOI
  108. Chellan, 2007, Galectin-1, an endogenous lectin produced by arterial cells, binds lipoprotein(a) [Lp(a)] in situ: relevance to atherogenesis, Exp Mol Pathol, 83, 399, 10.1016/j.yexmp.2007.04.004 · DOI
  109. Kalaivani, 2014, Circulating Lp(a):LDL complexes contain LDL molecules proportionate to Lp(a) size and bind to galectin-1: a possible route for LDL entry into cells, Lipids, 49, 1101, 10.1007/s11745-014-3941-4 · DOI
  110. Kang, 1997, Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells, Arterioscler Thromb Vasc Biol, 17, 2036, 10.1161/01.ATV.17.10.2036 · DOI
  111. Miles, 1989, A potential basis for the thrombotic risks associated with lipoprotein(a), Nature, 339, 301, 10.1038/339301a0 · DOI
  112. Miles, 1995, Interaction of Lp(a) with plasminogen binding sites on cells, Thromb Haemostasis, 73, 458, 10.1055/s-0038-1653797 · DOI
  113. Hajjar, 1991, The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen, J Biol Chem, 266, 21962, 10.1016/S0021-9258(18)54731-1 · DOI
  114. Plow, 2012, So many plasminogen receptors: why?, J Biomed Biotechnol, 2012, 141806
  115. Sharma, 2017, Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a), Circ Res, 120, 1091, 10.1161/CIRCRESAHA.116.310272 · DOI · Paper page
  116. Andronicos, 2010, Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation, Blood, 115, 1319, 10.1182/blood-2008-11-188938 · DOI
  117. Miles, 2017, Deficiency of plasminogen receptor, Plg-RKT , causes defects in plasminogen binding and inflammatory macrophage recruitment in vivo, J Thromb Haemostasis, 15, 155, 10.1111/jth.13532 · DOI
  118. Flood, 2011, The annexin A2 system and vascular homeostasis, Vasc Pharmacol, 54, 59, 10.1016/j.vph.2011.03.003 · DOI
  119. Hajjar, 1999, Annexin II: a mediator of the plasmin/plasminogen activator system, Trends Cardiovasc Med, 9, 128, 10.1016/S1050-1738(99)00020-1 · DOI
  120. Mayer, 2008, Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels, J Biol Chem, 283, 31791, 10.1074/jbc.M805971200 · DOI · Paper page
  121. White, 1999, Presecretory degradation of apolipoprotein [a] is mediated by the proteasome pathway, J Lipid Res, 40, 275, 10.1016/S0022-2275(20)33367-8 · DOI
  122. White, 1993, Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes, J Lipid Res, 34, 509, 10.1016/S0022-2275(20)40742-4 · DOI
  123. Fazio, 2000, The cell biology and physiologic relevance of ApoE recycling, Trends Cardiovasc Med, 10, 23, 10.1016/S1050-1738(00)00033-5 · DOI
  124. Kostner, 1996, Urinary excretion of apo(a) fragments. Role in apo(a) catabolism, Arterioscler Thromb Vasc Biol, 16, 905, 10.1161/01.ATV.16.8.905 · DOI
  125. Moriarty, 2017, Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients, Arterioscler Thromb Vasc Biol, 37, 580, 10.1161/ATVBAHA.116.308704 · DOI · Paper page
  126. Bennet, 2007, Association of apolipoprotein E genotypes with lipid levels and coronary risk, JAMA, 298, 1300, 10.1001/jama.298.11.1300 · DOI · Paper page
  127. Reyes-Soffer, 2017, The metabolism of lipoprotein (a): an ever-evolving story, J Lipid Res, 58, 1756, 10.1194/jlr.R077693 · DOI

Cited by

Sorted by citations

Metadata

Authors
McCormick, S. P. A., & Schneider, W. J.
ORCID
Schneider, Wolfgang J.
Venue
Pathology
Publisher
Elsevier BV
Published
2019-02
Volume
51
Issue
2
Pages
155-164
ISSN
0031-3025
DOI
10.1016/j.pathol.2018.11.003
Cited by
107
References
13
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
University of Otago

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review